150 research outputs found
Wireless resource virtualization: opportunities, challenges, and solutions
Wireless resource virtualization (WRV) is currently emerging as a key technology to overcome the major challenges facing the mobile network operators (MNOs) such as reducing the capital, minimizing the operating expenses, improving the quality of service, and satisfying the growing demand for mobile services. Achieving such conflicting objectives simultaneously requires a highly efficient utilization of the available resources including the network infrastructure and the reserved spectrum. In this paper, the most dominant WRV frameworks are discussed where different levels of network infrastructure and spectrum resources are shared between multiple MNOs. Moreover, we summarize the major benefits and most pressing business challenges of deploying WRV. We further highlight the technical challenges and requirements for ion and sharing of spectrum resources in next generation networks. In addition, we provide guidelines for implementing comprehensive solutions that are able to and share the spectrum resources in next generation network. The paper also presents an efficient algorithm for base station virtualization in longâterm evolution (LTE) networks to share the wireless resources between MNOs who apply different scheduling polices. The proposed algorithm maintains a highâlevel of isolation and offers throughput performance gain. Copyright © 2016 John Wiley & Sons, Ltd. Wireless resource virtualization (WRV) is emerging as a key technology to reduce cost and increase the total network capacity by sharing wireless resources between multiple mobile operators. In this paper, we present the concepts, highlight the benefits, and discuss the technical challenges and requirements for ion and sharing of WRV in next generation networks. Furthermore, an efficient WRV approach for longâterm evolution base stations is proposed and evaluated
Pregnancy in patients with myelofibrosis: MayoâFlorence series of 24 pregnancies in 16 women
n/
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Hypomethylating agents in relapsed and refractory AML: Outcomes and their predictors in a large international patient cohort
TP53 mutation variant allele frequency of >/-10% is associated with poor prognosis in therapy-related myeloid neoplasms
Published online: 11 April 2023Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International Consensus Classification (ICC) and the World Health Organization (WHO) recommended major change pertaining to TP53-mutated (TP53mut) MN. However, these assertions have not been specifically examined in therapy-related myeloid neoplasm (t-MN), a subset enriched with TP53mut. We analyzed 488 t-MN patients for TP53mut. At least one TP53mut with variant allele frequency (VAF)ââ„â2% with or without loss of TP53 locus was noted in 182 (37.3%) patients and 88.2% of TP53mut t-MN had a VAF â„10%. TP53mut t-MN with VAFââ„â10% had a distinct clinical and biological profile compared to both TP53mut VAFâ10% blasts had inferior survival compared to <5%. In summary, TP53mut VAF â„10% signified a clinically and molecularly homogenous cohort regardless of the allelic status.Mithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, Rakchha Chhetri, Anmol Baranwal, Dariusz Ladon, Carl Shultz, Aref Al-Kali, Anna L. Brown, Dong Chen, Hamish S. Scott, Patricia Greipp, Daniel Thomas, Hassan B. Alkhateeb, Deepak Singhal, Naseema Gangat, Sharad Kumar, Mrinal M. Patnaik, Christopher N. Hahn, Chung Hoow Kok, Ayalew Tefferi and Devendra K. Hiwas
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Abstract Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) following HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients underwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative in 43%. Patients received matched unrelated donor, matched sibling, haploidentical and mismatched unrelated HSCT in 56%, 24%, 16% and 4% of cases, respectively. Acute GvHD and chronic GvHD were observed in 40% and 17% of patients. While the median OS for the entire cohort of patients was 15.3 months (95% CI 9.5 â 21.7 months), OS reached 29.7 months (95% CI 7.01 â not-reached) for patients who achieved a complete remission (CR) to HMA and no intervening therapies between HMA therapy and HSCT. Our study suggests that HMA therapy can effectively bridge some patients with RR-AML to HSCT
Suppression of charged particle production at large transverse momentum in central Pb-Pb collisions at TeV
Inclusive transverse momentum spectra of primary charged particles in Pb-Pb
collisions at = 2.76 TeV have been measured by the ALICE
Collaboration at the LHC. The data are presented for central and peripheral
collisions, corresponding to 0-5% and 70-80% of the hadronic Pb-Pb cross
section. The measured charged particle spectra in and GeV/ are compared to the expectation in pp collisions at the same
, scaled by the number of underlying nucleon-nucleon
collisions. The comparison is expressed in terms of the nuclear modification
factor . The result indicates only weak medium effects ( 0.7) in peripheral collisions. In central collisions,
reaches a minimum of about 0.14 at -7GeV/ and increases
significantly at larger . The measured suppression of high- particles is stronger than that observed at lower collision energies,
indicating that a very dense medium is formed in central Pb-Pb collisions at
the LHC.Comment: 15 pages, 5 captioned figures, 3 tables, authors from page 10,
published version, figures at http://aliceinfo.cern.ch/ArtSubmission/node/98
Two-pion Bose-Einstein correlations in central Pb-Pb collisions at = 2.76 TeV
The first measurement of two-pion Bose-Einstein correlations in central Pb-Pb
collisions at TeV at the Large Hadron Collider is
presented. We observe a growing trend with energy now not only for the
longitudinal and the outward but also for the sideward pion source radius. The
pion homogeneity volume and the decoupling time are significantly larger than
those measured at RHIC.Comment: 17 pages, 5 captioned figures, 1 table, authors from page 12,
published version, figures at
http://aliceinfo.cern.ch/ArtSubmission/node/388
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
- âŠ